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Abstract
Background: Although many case reports have described patients with proton pump inhibitor (PPI)-induced
hypomagnesemia, the impact of PPI use on hypomagnesemia has not been fully clarified through comparative studies.
We aimed to evaluate the association between the use of PPI and the risk of developing hypomagnesemia by conducting a
systematic review with meta-analysis.
Methods: We conducted a systematic search of MEDLINE, EMBASE, and the Cochrane Library using the primary keywords
‘‘proton pump,’’ ‘‘dexlansoprazole,’’ ‘‘esomeprazole,’’ ‘‘ilaprazole,’’ ‘‘lansoprazole,’’ ‘‘omeprazole,’’ ‘‘pantoprazole,’’ ‘‘rabepra-
zole,’’ ‘‘hypomagnesemia,’’ ‘‘hypomagnesaemia,’’ and ‘‘magnesium.’’ Studies were included if they evaluated the association
between PPI use and hypomagnesemia and reported relative risks or odds ratios or provided data for their estimation.
Pooled odds ratios with 95% confidence intervals were calculated using the random effects model. Statistical heterogeneity
was assessed with Cochran’s Q test and I2 statistics.
Results: Nine studies including 115,455 patients were analyzed. The median Newcastle-Ottawa quality score for the
included studies was seven (range, 6–9). Among patients taking PPIs, the median proportion of patients with
hypomagnesemia was 27.1% (range, 11.3–55.2%) across all included studies. Among patients not taking PPIs, the median
proportion of patients with hypomagnesemia was 18.4% (range, 4.3–52.7%). On meta-analysis, pooled odds ratio for PPI use
was found to be 1.775 (95% confidence interval 1.077–2.924). Significant heterogeneity was identified using Cochran’s Q
test (df = 7, P,0.001, I2 = 98.0%).
Conclusions: PPI use may increase the risk of hypomagnesemia. However, significant heterogeneity among the included
studies prevented us from reaching a definitive conclusion.
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Introduction
Proton pump inhibitors (PPIs) are a mainstay of treatment for
acid-related diseases, including gastroesophageal reflux disease,
functional dyspepsia, and peptic ulcer disease [1–5]. PPIs have an
excellent safety profile, and have become one of the most
commonly prescribed class of drugs in both primary and specialty
care [6]. However, PPI use may induce some adverse events,
including interstitial nephritis [7], respiratory infections [8],
Clostridium difficile colitis [9], and hip fractures [10]. More
recently, it has been reported that hypomagnesemia may also be
induced by PPIs. The association between symptomatic hypo-
magnesemia and PPI use was first described in two patients in
2006 [11]. Since this report, many case reports have accumulated,
supporting the association between PPI use and induced
hypomagnesemia [12–16]. The Food and Drug Administration
issued a Drug Safety Communication in 2011 [17], emphasizing
the importance of long term use of prescription PPIs in this
association. Moreover, a systematic review of 18 case reports of
PPI-induced hypomagnesemia found that discontinuation of PPI
use resulted in recovery from PPI-induced hypomagnesemia [18].
Although the pathophysiology of PPI-induced hypomagnesemia
has not been definitively determined, impaired absorption of
intestinal magnesium, due to administration of PPIs, may be one
possible mechanism [19]. Decreased luminal pH in the intestine,
caused by PPI use, may alter the affinity of the transient receptor
potential melastatin-6 and transient receptor potential melastatin-
7 (TRPM6/7) channel for Mg2+, reducing active transport of
Mg2+ [20,21].
Although many case reports have described patients with PPI-
induced hypomagnesemia, the impact of PPI use on hypomagne-
semia has not been fully clarified in comparative studies [22–30].
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In some studies, the association between PPI use and hypomag-
nesemia was not identified [23–25,29], while in others, PPI use
was found to increase the risk of hypomagnesemia [22,26–28,30].
The discrepancy between these studies may be attributed to
various patient characteristics, and/or underlying conditions.
To examine this topic, we performed a systematic review with
meta-analysis, of existing comparative studies that investigated the
association between PPI use and the risk of developing hypomag-
nesemia.
Materials and Methods
Search strategy
We searched for all relevant studies published between January
1990 and May 2014 that examined the effect of PPI use on the risk
of hypomagnesemia, using MEDLINE, EMBASE, and the
Cochrane Library. The terms ‘‘proton pump,’’ ‘‘dexlansoprazole,’’
‘‘esomeprazole,’’ ‘‘ilaprazole,’’ ‘‘lansoprazole,’’ ‘‘omeprazole,’’
‘‘pantoprazole,’’ ‘‘rabeprazole,’’ ‘‘hypomagnesemia,’’ ‘‘hypomag-
nesaemia,’’ and ‘‘magnesium’’ were used in our search. We also
examined the references of screened articles, in order to identify
additional studies. All human studies published in English were
considered, and the latest date for updating our search was August
19, 2014.
Study selection
In the first stage of the study selection, the titles and abstracts of
papers returned by our keyword search were examined to exclude
irrelevant articles. Next, the full-text of all selected studies was
screened, according to our inclusion and exclusion criteria. The
inclusion criteria specified (1) studies regarding PPIs and
hypomagnesemia, and (2) studies reporting relative risks or odds
ratios (ORs) of PPI use, or provided data for their calculation. The
exclusion criteria ruled out publications in a language other than
English. Two investigators (C.H.P. and E.H.K.) independently
evaluated studies for eligibility, resolved any disagreements
through discussion and consensus. If no agreement could be
reached, a third investigator (S.K.L.) decided eligibility.
To understand the risk of bias in individual studies, a formal
quality assessment of studies was performed, along with subgroup
analysis. The methodological quality of observational studies was
independently assessed by two investigators (C.H.P. and E.H.K.),
using the Newcastle-Ottawa scale [31,32]. Using this scale,
observational studies were scored across three categories: selection
(4 questions), comparability of study groups (2 questions), and
ascertainment of the exposure or outcome (3 questions). All
questions were assigned a score of one point, with the exception of
comparability of study groups, in which a maximum of two points
were awarded. Studies with a cumulative score $7 were
considered high quality [33,34].
Figure 1. Flow diagram of studies included in the meta-analysis. PPI, proton pump inhibitor.
doi:10.1371/journal.pone.0112558.g001
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Data extraction
Using a data extraction form developed in advance, two
reviewers (C.H.P. and E.H.K.) independently extracted the
following information: first author, year of publication, study
design, country, enrollment period, study population, age and sex
of patients, definition of hypomagnesemia, total number of
patients in each group (exposed vs. not exposed), ORs, and 95%
confidence intervals (CIs). When incomplete information was
available, attempts were made to contact the corresponding
authors of the studies for additional information.
Outcomes assessed
Our primary analysis focused on assessing the risk of
hypomagnesemia among users of PPIs. Our a priori hypothesis
included study population (inpatients vs. others) as a potential
explanation for heterogeneity in the direction and magnitude of
effect. For exploratory analysis we conducted subgroup analysis
according to the cut-off value of serum magnesium level (1.7 mg/
dL vs. 1.8 mg/dL).
Statistical analysis
Meta-analyses were performed to calculate pooled ORs with
95% CIs [35]. Taking a conservative approach, we used a random
effects model, which produces wider CIs than a fixed effect model.
We assessed heterogeneity using two methods: Cochran’s Q test,
which was considered statistically significant for heterogeneity if
P,0.1, and I2 statistics, with values.50% suggestive of significant
heterogeneity [36]. The tests for funnel plot asymmetry was not
conducted when the included studies were less than 10 [37]. All P-
values were 2-tailed, and a value of P,0.05 was considered
statistically significant for all tests (except heterogeneity). Analysis
and reporting were performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [38]. Statistical analyses were conducted
using the statistical software Comprehensive Meta Analysis
(version 2.2.064; Biostat Inc., Englewood, NJ, USA).
Results
Study selection
A flow diagram for our systematic review is shown in Fig. 1. In
summary, 409 studies were identified by our literature search.
After scanning titles and abstracts, we discarded 101 duplicate
articles retrieved through multiple search engines. Another 295
irrelevant articles were excluded based on the titles and abstracts.
The full texts of the 13 remaining articles were reviewed, and 4
non-pertinent articles were excluded. Of 4 excluded studies, three
were non-comparative studies without control group and remain-
ing one included none of the patients with hypomagnesemia in
both treatment and control group.
Of the original 409 studies, nine studies were deemed
appropriate for our meta-analysis [22–25,27,28]. These studies
included a total of 115,455 patients, and all had been published in
the past 2 years, between 2012 and 2014. The enrollment period
for these studies ranged from 2000 to 2013, and all were
retrospective in nature. Of the included studies, five included only
hospitalized patients [22–25,30], two included outpatients only
[28,29], one included both inpatients and outpatients [26], and
one included patients with end-stage renal disease on hemodial-
ysis, but did not provide data regarding the hospitalization of
patients [27]. The median Newcastle-Ottawa quality score for
these studies was seven (range, 6–9), and all studies except one
were considered high quality. The characteristics of the studies
included in the meta-analysis are summarized in Table 1.
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Risk of hypomagnesemia
The cut-off value of serum magnesium level for defining
hypomagnesemia was 1.6, 1.7, and 1.8 mg/dL in one [25], five
[22,24,26,28,29], and three studies [23,27,30], respectively
(Table 2). Among patients taking PPIs, the median proportion of
patients with hypomagnesemia in all included studies was 27.1%
(range, 11.3–55.2%). In addition, the median of the proportion of
patients with hypomagnesemia in those not taking PPIs was 18.4%
(range, 4.3–52.7%) across the studies. Of 9 included studies, six
reported both unadjusted OR and adjusted OR. Other two studies
showed unadjusted OR only. Remaining one study showed
adjusted OR only. Most studies adjusted for the following
confounders: use of diuretics (6/7), renal function (5/7), age
(4/7), diabetes mellitus (4/7), and comorbidities (4/7). On meta-
analysis, pooled unadjusted OR for PPI use was found to be 1.775
(95% CI= 1.077–2.924). Significant heterogeneity was identified
(Cochran’s Q test, df = 7, P,0.001, I2 = 98.0%). This risk increase
with PPI use persisted even after adjusting for potential
confounders where reported in studies (pooled adjusted OR
[95% CI] = 1.484 [1.103–1.997], Fig. 2), although the heteroge-
neity persisted (Cochran’s Q test, df = 6, P,0.001, I2 = 89.1%).
Subgroup analysis
We performed pre-planned subgroup analysis of studies, based
on the hospitalization of patients. In five studies which included
only hospitalized patients [22–25,30], PPI use was not associated
with hypomagnesemia (pooled unadjusted OR [95% CI] = 1.342
[0.895–2.011]). Significant heterogeneity did exist in the inpatient
subgroup (Cochran’s Q test, df = 4, P,0.001, I2 = 92.0%). Pooled
adjusted OR showed similar results between PPI use and incidence
of hypomagnesemia compared to pooled unadjusted OR (pooled
adjusted OR [95% CI] = 1.424 [0.924–2.196], Fig. 3). Significant
heterogeneity persisted in this analysis (Cochran’s Q test, df = 3,
P,0.001, I2 = 88.3%).
For exploratory analysis, we performed additional subgroup
analysis according to the cut-off value of serum magnesium level.
In 4 studies which reported adjusted OR based on the 1.7 mg/dL
of cut-off value [22,24,28,29], PPI use was not associated with
incidence of hypomagnesemia (pooled adjusted OR [95%
CI] = 1.363 [0.827–2.246], Fig. 4A). Significant heterogeneity
was identified in this subgroup (Cochran’s Q test, df = 3, P,
0.001, I2 = 87.7%). In 2 studies which showed adjusted ORs based
on the 1.8 mg/dL of cut-off value [27,30], on the contrary, PPI
use increased the risk of hypomagnesemia (pooled adjusted OR
[95% CI] = 2.292 [1.632–3.218], Fig. 4B). There was no hetero-
geneity in this subgroup (Cochran’s Q test, df = 1, P=0.339,
I2 = 0.0%).
Discussion
Intracellular magnesium is an important cofactor for enzymatic
reactions, and is critical for energy metabolism involving
adenosine triphosphate [19]. Magnesium homeostasis is deter-
mined primarily by two processes, gastrointestinal absorption and
renal excretion [39]. Gastrointestinal magnesium absorption
occurs through both passive paracellular movement, and active
transport into the portal venous system [19]. Active magnesium
transport in the gut occurs through the combined action of
TRPM6/7 channels, which are present in the apical membrane of
enterocytes [39]. Previous studies have found that renal excretion
of magnesium is reduced appropriately in patients with PPI-
induced hypomagnesemia [40,41], and that a PPI-induced
decrease in the luminal pH of the intestine might alter the
TRPM6/7 channel’s affinity for magnesium [21]. Therefore,
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impaired intestinal absorption rather than renal excretion is
considered the primary cause of PPI-induced hypomagnesemia.
Many previous case reports [12–16], and proposed mechanisms
of PPI-induced hypomagnesemia, have promoted awareness of the
risk of hypomagnesemia in patients taking PPIs. However, the risk
for PPI-induced hypomagnesemia should be evaluated by
comparative studies, since the prevalence of hypomagnesemia is
not rare. One previous population-based study found that 2% of
subjects (104 of 5,179) have hypomagnesemia [42]. Other
population-based studies also have suggested that hypomagnese-
mia is not rare in the general population [43,44]. Moreover, in
hospitalized patients, electrolyte disorders (including hypomagne-
semia) are often acute and severe. Therefore, case reports alone
cannot analyze the effect of PPI use on hypomagnesemia, and
well-designed, comparative studies are needed to clarify the risk of
PPI-induced hypomagnesemia.
Our meta-analysis showed statistical significance between PPI
use and the risk of hypomagnesemia. The risk of hypomagnesemia
in PPI users persisted even after adjusting for confounding
variables. However, the significant heterogeneity among the
included studies may be a concern. The significance of heteroge-
neity implied that the effect of PPI use on hypomagnesemia was
varied. The observed heterogeneity may be due to the various
types of study design and population among our included studies.
For example, Gau et al.’s study [22], Koulouridis et al.’s study
[24], and Lindner et al.’s study [30] included hospitalized patients,
regardless of disease type. However, Koulouridis et al.’s study was
designed as case-control study, while other two studies were
designed as cross-sectional study. In contrast, Danziger et al.’s
study [25] included only patients admitted to intensive care units.
El-Charabaty et al.’s study [23] included only hospitalized patients
with unstable angina, non-ST elevation myocardial infarction, and
ST elevation myocardial infarction. Kim et al.’s study [26]
included both inpatients and outpatients. Alhosaini et al.’s study
[27] included only patients with end-stage renal disease on
hemodialysis. Van Ende et al.’s study [29] included only renal
transplant recipients. Finally, Markovitis et al.’s study [28]
included only outpatients in the community setting. In addition,
the definition of hypomagnesemia was varied among the included
studies. These variations in study design may be reflected in the
proportion of patients with hypomagnesemia for each group
(patients taking PPIs vs. those not taking PPIs). The proportion of
patients with hypomagnesemia ranged from 11.3% to 55.2% (PPI
user group), and from 4.1% to 52.7% (non-PPI user group), and
therefore, we believe that the incidence or prevalence of
hypomagnesemia may depend on the study design.
One of the clinical concerns on PPI-induced hypomagnesemia
is whether the test for serum magnesium level should be performed
before initiating PPIs or not. Although it has not been fully
evaluated, experts usually recommend the test for serum
magnesium level prior to initiation of PPIs when patients are
expected to be on treatment for long period of time [45,46]. While
short-term standard dose PPI treatment has low risk, long-term
PPI use may complicate health conditions in high risk patients for
hypomagnesemia including elderly patients [46]. The inter-study
differences in the proportion of patients with hypomagnesemia in
our meta-analysis may suggest that there are patients with
increased susceptibility to PPI-induced hypomagnesemia. Consid-
ering the excellent safety profile of PPIs, risk identification and
stratification for PPI-induced hypomagnesemia may be more
helpful for clinical practice, rather than investigation of PPI-
induced hypomagnesemia in the general population. Kim et al.’s
study, which evaluated associated factors for hypomagnesemia,
found that long-term PPI use (.1 year), young age (,45 years),
Figure 2. Forest plots for risk of hypomagnesemia. PPI, proton pump inhibitor; CI, confidence interval.
doi:10.1371/journal.pone.0112558.g002
Figure 3. Subgroup analysis for studies which included only hospitalized patients. PPI, proton pump inhibitor; CI, confidence interval.
doi:10.1371/journal.pone.0112558.g003
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and concurrent cisplatin or carboplatin use were associated with
hypomagnesemia in PPI users [26]. However, the study only
included PPI users whose serum magnesium levels were available,
and therefore, selection bias may be a concern. A population
based study with regular checkup for serum magnesium level may
be needed for clarifying the high risk patients for PPI-induced
hypomagnesemia.
In our study, we conducted the two types of subgroup analysis.
The former was subgroup analysis for studies which included
hospitalized patients only, while the latter was subgroup analysis
according to the cut-off value of serum magnesium level. In the
former subgroup analysis, statistical significance between PPI use
and the risk of hypomagnesemia was not shown. Although the
subgroup included only hospitalized patients, the variation among
the studies was still existed. In the latter subgroup analysis, PPI use
increased the risk of hypomagnesemia in the studies whose cut-off
value was 1.8 mg/dL rather than 1.7 mg/dL. These results
implied that PPI-induced hypomagnesemia might not be as severe
as we were concerned; however, further studies would be needed
for assessing the severity of PPI-induced hypomagnesemia.
Although this is the first meta-analysis which demonstrated that
PPI use could increase the risk of hypomagnesemia, there are
several limitations. First, this is the meta-analysis for observational
studies rather than randomized controlled trials. Magnesium
assessment in a large database is usually healthcare-driven and
potentially biased. In addition, dyspepsia may lead to prescribing
PPIs as well as deficient food intake with low magnesium ingestion.
Furthermore, serum magnesium was not usually evaluated in
clinical practice. Although we conducted a meta-analysis using the
adjusted ORs in the included studies, potential issues of
confounding variables may be exist. The conclusion from the
meta-analysis for observational studies should be interpreted
carefully. Second, the significant heterogeneity among the
included studies was additional obvious limitation. Through our
systematic review and meta-analysis, we found that the proportion
of patients with hypomagnesemia depended on the study settings
including patient population and characteristics. Prospective
cohort studies will be needed to evaluate severity of PPI-induced
hypomagnesemia and to identify high risk group for PPI-induced
hypomagnesemia. Third, we could not assess the risk of PPI-
induced hypomagnesemia according to the amount or duration of
usage of PPIs because available data were limited in the included
studies.
Despite of these limitations, our meta-analysis showed that PPI
use may increase the risk of hypomagnesemia. However,
significant heterogeneity among the included studies prevented
us from reaching a definitive conclusion. Well-designed, prospec-
tive cohort studies, which include regular serum magnesium
monitoring, would provide more conclusive results.
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